Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Imbruvica (Pharmacyclics)
- INDICATIONS: Mantle cell lymphoma
- CLASS: Bruton's tyrosine kinase (BTK) inhibitor
- HALF-LIFE: 4–6 hours
- FDA APPROVAL DATE: 11/14/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clarithromycin, Grapefruit Juice, Itraconazole, Ketoconazole, Phenytoin, Posaconazole, Rifampin, St John's Wort, Strong or moderate CYP3A inhibitors or inducers, Telithromycin, Viloxazine, Voriconazole
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ibrutinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/27/2025
